Home › NDC Lookup › RxCUI directory › RxCUI 1721434

Methenamine 162 MG / sodium salicylate 162.5 MG Oral Tablet [Azo Urinary Tract Defense] — RxCUI 1721434

RxNorm drug concept · Semantic branded drug
RxCUI 1721434 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1721434
Official nameMethenamine 162 MG / sodium salicylate 162.5 MG Oral Tablet [Azo Urinary Tract Defense]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAzo Urinary Tract Defense 162 MG / 162.5 MG Oral Tablet
FDA products mapped1
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Salicylic Acid Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's designed to treat acne. Salicylic acid helps by loosening and removing dead skin cells that clog pores — the buildup that leads to breakouts. The multi-step system on this lab...
  • What is this salicylic acid product actually supposed to do for my skin?
  • Some mild tingling, stinging, and peeling is actually expected — that's the salicylic acid doing its job by clearing away dead skin cells. But if the burning or peeling feels exces...
  • My skin feels like it's burning and peeling. Is that normal?
📖 Read our full Salicylic Acid Topical guide →

🕸️ Concept Web — How Methenamine 162 MG / sodium salicylate 162.5 MG... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Methenamine 162 MG / sodium salicylate 162.5 MG Oral Tablet [Azo Urinary Tract Defense] RxCUI 1721434

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Methenamine 6832
    • Salicylic acid 9525
    • Methenamine / salicylic acid 1007803
    • Sodium salicylate 9907
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Azo Urinary Tract Defense 1721429
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Methenamine / salicylic acid Oral Tablet 991473
    • Methenamine / sodium salicylate Oral Tablet 2647349
    • Methenamine / salicylic acid Oral Product 1162205
    • Methenamine / salicylic acid Pill 1162206
    • Methenamine / sodium salicylate Oral Product 2663103
    • Methenamine / sodium salicylate Pill 2660342
    • Methenamine / salicylic acid Oral Tablet [Azo Urinary Tract Defense] 1721431
    • Methenamine / sodium salicylate Oral Tablet [Azo Urinary Tract Defense] 2657390
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Methenamine 162 MG / sodium salicylate 162.5 MG Oral Tablet SCD · 1489932
  • Methenamine 162 MG SCDC · 335955
  • Sodium salicylate 162.5 MG SCDC · 1489931
  • Methenamine / salicylic acid Oral Tablet SCDF · 991473
  • Methenamine / sodium salicylate Oral Tablet SCDFP · 2647349
  • Methenamine / salicylic acid Oral Product SCDG · 1162205
  • Methenamine / salicylic acid Pill SCDG · 1162206
  • Methenamine / sodium salicylate Oral Product SCDGP · 2663103
  • Methenamine / sodium salicylate Pill SCDGP · 2660342

Brand-Name Concepts

  • Methenamine 162 MG / sodium salicylate 162.5 MG [Azo Urinary Tract Defense] SBDC · 1721430
  • Methenamine / salicylic acid Oral Tablet [Azo Urinary Tract Defense] SBDF · 1721431
  • Methenamine / sodium salicylate Oral Tablet [Azo Urinary Tract Defense] SBDFP · 2657390
  • Azo Urinary Tract Defense Oral Product SBDG · 1721432
  • Azo Urinary Tract Defense Pill SBDG · 1721433
  • Azo Urinary Tract Defense BN · 1721429

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 1721434 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49973-0011-18 1 BLISTER PACK in 1 BOX (49973-011-18) / 18 TABLET in 1 BLI... Azo Urinary Tract Defense Antibacterial Protection i-Health, Inc. 2018-04-23
49973-0011-24 1 BLISTER PACK in 1 BOX (49973-011-24) / 24 TABLET in 1 BLI... Azo Urinary Tract Defense Antibacterial Protection i-Health, Inc. 2016-03-01
49973-0011-48 2 BLISTER PACK in 1 BOX (49973-011-48) / 24 TABLET in 1 BLI... Azo Urinary Tract Defense Antibacterial Protection i-Health, Inc. 2025-12-15
Observed labelers: i-Health, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.